The European Bank for Reconstruction and Development (EBRD) announced the acquisition with other partners of Egypt’s Adwia Pharmaceuticals company to improve the availability and affordability of medicines, using an investment platform with an initial capital commitment of $250 million.

In a statement on Monday, the EBRD said it is committing $75 million to support the company’s growth in Egypt, alongside Development Partners International (DPI), a pan-African private equity firm which is committing $75 million, and CDC Group, a development finance institution funded by the UK government, with $100 million commitment.

The total worth of the deal is $250 million.

As a first step for the investment platform the partners have acquired Adwia Pharmaceuticals, an Egyptian manufacturer of generic drugs, and Celon Laboratories, an Indian oncology and critical-care product specialist, according to the statement.

Adwia will benefit from Celon’s know-how in drug development, including for chronic and life-threatening health conditions, said EBRD.

It added that this investment will also help Adwia Pharmaceuticals to expand and modernise its manufacturing assets, introduce products with higher added value and improve its health and safety standards, product quality and governance in Egypt.

Moreover, founding shareholders plan to increase their impact by further expanding the investment platform’s activities, according to the statement.

Egypt is a founding member of the EBRD. Since the start of the bank’s operations in 2012, the EBRD has invested over €7 billion in 125 projects in the country.